| Osmond Resources Limited (OSM) ORDINARY FULLY PAID |
Materials |
$85 |
High-Grade Assay Results Continue at Orion Project
|
28 Apr 2026 9:40AM |
$0.600 |
$0.610 |
risen by
1.67%
|
|
OSM - Price-sensitive ASX Announcement
Full Release
Key Points
- Osmond Resources Limited has announced the final assay results from Phase 1 drilling at the Orión EU Critical Minerals Project.
- The drill holes NWOR-04bis, NWOR-01, NWOR-02, and SOR-01 highlight the project's potential to contain significant critical and strategic mineral resources, including zirconium, rare earth elements, and titanium.
- High-grade mineralization is confirmed over a ~10km distance from AV-01 to NWOR-04bis.
- Drill hole NWOR-02 identified the first intersection of the Basal Seam in the lower Pochico Formation, enhancing the project's regional prospectivity.
- Phase 2 drilling is scheduled to commence in the coming weeks.
- Quality control for assays involved standards, blanks, duplicates, and external laboratory checks, ensuring accuracy and precision.
- Mineralization includes heavy minerals such as rutile, ilmenite, zircon, and monazite.
- Assay highlights include significant percentages of TiO2 and ZrO2 along with various rare earth elements from multiple drill holes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| archTIS Limited (AR9) ORDINARY FULLY PAID |
Information Technology |
$25 |
Investor Webinar
|
28 Apr 2026 9:40AM |
$0.060 |
$0.051 |
fallen by
15%
|
|
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$62 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Apr 2026 9:38AM |
$0.165 |
$0.120 |
fallen by
27.27%
|
|
ATX - Price-sensitive ASX Announcement
Full Release
Key Points
- Amplia Therapeutics Limited is developing narmafotinib, a FAK inhibitor, for fibrotic cancers like pancreatic cancer.
- The ACCENT trial showed narmafotinib with chemotherapy improved survival rates in pancreatic cancer patients.
- The AMPLICITY trial, exploring narmafotinib with FOLFIRINOX, faced challenges with dose-limiting toxicity.
- Amplia's cash position is strong with $27.9 million as of March 2026, despite $3.5 million in net operating cash outflows.
- Significant funds were allocated to research, development, and administration costs.
- Large-scale production of narmafotinib to GMP standards has been completed, enhancing readiness for Phase 3 trials.
- The company is focusing on regulatory engagement with the US FDA and planning new clinical studies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Muzinich BDC Income Fund - Active ETF (BDCI) MUZINICH BDC INCOME FUND - ACTIVE ETF |
- |
$3 |
Distribution for month ending 30 April 2026
|
28 Apr 2026 9:38AM |
$19.910 |
$19.310 |
fallen by
3.01%
|
|
| Switzer Dividend Growth Fund (Managed Fund) (SWTZ) |
Financials |
$54 |
Distribution for month ending 30 April 2026
|
28 Apr 2026 9:38AM |
$2.460 |
$2.350 |
fallen by
4.47%
|
|
| Energy Resources of Australia Limited (ERA) ORDINARY FULLY PAID 'A' |
Energy |
$811 |
Appendix 3Y - Brad Welsh
|
28 Apr 2026 9:36AM |
$0.004 |
$0.002 |
fallen by
42.86%
|
|
| Fortifai Ltd (FTI) ORDINARY FULLY PAID |
Communication Services |
$269 |
Further Benchmark Results Prove Infrastructure Cost Savings
|
28 Apr 2026 9:36AM |
$0.715 |
$0.780 |
risen by
9.09%
|
|
FTI - Price-sensitive ASX Announcement
Full Release
Key Points
- FTI's Nol8 FPGA appliance can replace up to 60,000 CPUs for AI workloads.
- Nol8 delivers AI-grade data processing at significantly lower costs and footprint.
- Annual operating cost of the Nol8 is under A$37,000 compared to A$4.5m for CPUs.
- Further benchmark testing confirms infrastructure cost savings using Nol8.
- Nol8's technology addresses CPU bottlenecks in AI data processing.
- FortifAI Limited uses AI to enhance technology efficiencies and develop video games.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nexsen Limited (NXN) ORDINARY FULLY PAID |
Health Care |
$17 |
Quarterly Report - Q3 FY26
|
28 Apr 2026 9:35AM |
$0.215 |
$0.180 |
fallen by
16.28%
|
|
NXN - Price-sensitive ASX Announcement
Full Release
Key Points
- Nexsen ended the quarter with $5.73 million in cash reserves.
- Secured AU$500,000 grant for neonatal diagnostics and HK$6 million IGNITE Grant for Hong Kong expansion.
- StrepSure® test for Group B Streptococcus progressing towards FDA submission by Q4 2026.
- Global rollout strategy for StrepSure® targeting Hong Kong, Malaysia, and India.
- Advancing towards ISO 13485 certification to support regulatory approvals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Finder Energy Holdings Limited (FDR) ORDINARY FULLY PAID |
Energy |
$169 |
Trading Halt
|
28 Apr 2026 9:34AM |
$0.590 |
$0.305 |
fallen by
48.31%
|
|
FDR - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Finder Energy Holdings Limited.
- Trading halt is due to pending capital raising announcement.
- Halt in accordance with ASX Listing Rule 17.1.
- Expected to lift by normal trading on 30 April 2026.
- No known reason for halt not to be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Xamble Group Limited (XGL) CHESS DEPOSITARY INTERESTS 1:1 |
Communication Services |
$4 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Apr 2026 9:34AM |
$0.013 |
$0.007 |
fallen by
46.15%
|
|
XGL - Price-sensitive ASX Announcement
Full Release
Key Points
- Group revenue was A$1.64 million in Q1 CY2026, a decrease of 1% compared to the previous year.
- Underlying business EBITDA loss was A$0.17 million, reflecting higher operating costs.
- The Group received an A$306,000 drawdown from the Malaysian Digital Acceleration Grant.
- Cash flow from operating activities was almost neutral with a slight outflow of A$12,000.
- Three new commercial contracts in technology, education, and automotive sectors valued at A$1.17 million.
- Completion of 55.6% acquisition of YouthsToday, expanding influencer community.
- Adrian Tan appointed as Interim CEO to lead integration and AI transformation.
- Stable cash and cash equivalents at A$946,000 with additional credit facility available.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$31 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Apr 2026 9:33AM |
$0.485 |
$1.000 |
risen by
106.19%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Q3 FY26 dose sales up 60% compared to the previous year.
- Number of commercially active treatment centres increased by 56% over the last year.
- Strategic initiatives expected to lower the cost base by $3.4-3.9 million annually from FY27.
- Germany G-BA Trial anticipated to start in Q4 FY26.
- Renzo DeCarlo appointed as Global Head of Manufacturing and Operations.
- Strong early clinical results in Türkiye with high surgical conversion rates.
- TRIPP-FFX Trial completed Last Patient, Last Visit (LPLV) with results expected in Q4 FY26.
- New manufacturing facility anticipated to be operational in 1H FY27.
- Comparative study shows survival and disease control benefits with OncoSil™ Therapy.
- $8 million capital raised and $1.8 million R&D tax incentive received.
- Strong cash position of $9.3 million as of 31 March 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lowell Resources Fund (LRT) ORDINARY UNITS FULLY PAID |
Financials |
$104 |
LRT NAV Estimate - 24 April 2026
|
28 Apr 2026 9:32AM |
$2.280 |
$2.120 |
fallen by
7.02%
|
|
| Spheria Emerging Companies Limited (SEC) ORDINARY FULLY PAID |
Financials |
$140 |
Net Tangible Asset Backing
|
28 Apr 2026 9:32AM |
$2.390 |
$2.330 |
fallen by
2.51%
|
|
| Constellation Technologies Limited (CT1) ORDINARY FULLY PAID |
Information Technology |
$4 |
Change in substantial holding
|
28 Apr 2026 9:31AM |
$0.003 |
$0.003 |
fallen by
0%
|
|
| Skylark Minerals Limited (SKM) ORDINARY FULLY PAID |
Materials |
$35 |
Quarterly Activities Report
|
28 Apr 2026 9:31AM |
$0.270 |
$0.270 |
fallen by
0%
|
|
SKM - Price-sensitive ASX Announcement
Full Release
Key Points
- Maiden drilling program commenced at Zaranou Gold Project in Côte d'Ivoire.
- Initial drilling results confirm mineralisation extends significantly deeper and remains open in multiple directions.
- Zaranou project holds an inferred resource of 364,600 ounces of gold.
- Skylark is also advancing exploration at Maphai and Vavoua projects.
- Company is actively seeking new asset opportunities in West Africa.
- Recent capital raise maintains strong cash position for exploration activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomic Eagle Ltd (AEU) ORDINARY FULLY PAID |
Materials |
$182 |
Commencement of 30,000m drill program
|
28 Apr 2026 9:31AM |
$0.420 |
$0.475 |
risen by
13.10%
|
|
AEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Atomic Eagle Limited's 2026 drill program commenced at its Muntanga Uranium Project in Zambia.
- The drilling program targets 30,000 meters across three key areas: Chisebuka, Namakande, and Muntanga North.
- The program aims to expand the uranium resource base and test new exploration targets.
- The company reported a 24% increase in its total Mineral Resources to 58.8 million pounds of U3O8.
- The Chisebuka area will undergo infill drilling to convert known mineralization into a JORC-compliant Mineral Resource.
- Namakande and Muntanga North will see maiden drilling to explore new potential uranium deposits.
- Atomic Eagle is fully funded for its exploration programs in 2026 and 2027.
- The exploration will support Atomic Eagle's vision of developing a district-scale uranium mine.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PhosCo Ltd (PHO) ORDINARY FULLY PAID |
Materials |
$81 |
March 2026 Quarterly Activities and Cashflow Report
|
28 Apr 2026 9:31AM |
$0.130 |
$0.150 |
risen by
15.38%
|
|
PHO - Price-sensitive ASX Announcement
Full Release
Key Points
- Gasaat Phosphate Project in Tunisia supported by local communities and government
- KM and SAB prospects show promising phosphate mineralization
- Operating cash outflows of $714,000 and investing outflows of $501,000
- Net inflow of $4.67 million from financing activities
- Project strategically significant due to high-quality phosphate resources and location
- Phosphate critical for agriculture and battery production
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cullen Resources Limited (CUL) ORDINARY FULLY PAID |
Materials |
$4 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Apr 2026 9:30AM |
$0.008 |
$0.006 |
fallen by
25%
|
|
CUL - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash used in operating activities was negative $375,000 for the quarter.
- Proceeds from the sale of non-current assets totaled $1,500,000.
- Advances from directors provided a net cash inflow of $110,000, with repayments of $170,000.
- Cash and cash equivalents at the end of the period were $609,000.
- Payments to related parties during the quarter totaled $81,000.
- The company plans to continue drilling activities at the Yardilla Gold Project.
- An access agreement has been signed for exploration at the Marymia Inlier project.
- No proceeds were raised from equity securities or convertible debt securities during the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Horizon Gold Limited (HRN) ORDINARY FULLY PAID |
Materials |
$223 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Apr 2026 9:30AM |
$1.250 |
$1.140 |
fallen by
8.80%
|
|
HRN - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of deep diamond drilling at Kingfisher and Omega prospects.
- Initiation of resource expansion drilling at Eagle South and Goldfinch prospects.
- Advancement of the Gum Creek Feasibility Study, on schedule for H1 CY 2026.
- High-grade gold mineralization confirmed at Kingfisher.
- Capital raising of $30 million announced to support studies and exploration.
- Appointment of Scott Williamson as CEO and Managing Director.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Skylark Minerals Limited (SKM) ORDINARY FULLY PAID |
Materials |
$35 |
Quarterly Cashflow Report
|
28 Apr 2026 9:30AM |
$0.270 |
$0.270 |
fallen by
0%
|
|
SKM - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash outflow from operating activities was $647,000 for the quarter.
- No receipts from customers were recorded.
- Significant cash outflows in staff and administration costs.
- Investing activities saw a $1,139,000 outflow for exploration.
- Net cash outflow from investing activities for the nine months was $7,669,000.
- Financing activities raised $6,427,000 primarily through equity issuance.
- Cash balance at end of the period increased to $7,531,000.
- Payments to related parties for the quarter were $149,000.
- Estimated 4.2 quarters of funding available.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| H3 Energy Limited (H3E) ORDINARY FULLY PAID |
Energy |
$8 |
Trading Halt
|
28 Apr 2026 9:29AM |
$0.010 |
$0.006 |
fallen by
40%
|
|
H3E - Price-sensitive ASX Announcement
Full Release
Key Points
- H3 Energy Limited requested a trading halt on its shares.
- The halt is due to an upcoming announcement regarding Capital Raising.
- Trading halt remains until the announcement or 30 April 2026.
- The trading halt request is in accordance with ASX Listing Rule 17.1.
- Board of H3 Energy Limited approved the trading halt request.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID |
Health Care |
$67 |
Quarterly Activities Report and Appendix 4C
|
28 Apr 2026 9:29AM |
$0.035 |
$0.041 |
risen by
18.84%
|
|
ENP - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant progress in TRP-8803 clinical trial for Binge Eating Disorder.
- Completion of Phase 2 BED trial Cohort 1 enrollment.
- Publication of positive Phase 2a results for TRP-8802.
- Grant of Australian patent for IV dosing method valid until 2042.
- Financial position supported by R&D tax incentive and funding facilities.
- Net increase in cash and cash equivalents reported for the quarter.
- Focus on clinical execution and IP strengthening.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Great Divide Mining Ltd (GDM) ORDINARY FULLY PAID |
Materials |
$23 |
Challenger Tax Liability and ADG Indemnity
|
28 Apr 2026 9:28AM |
$0.365 |
$0.330 |
fallen by
9.59%
|
|
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,754 |
Appendix 3C
|
28 Apr 2026 9:28AM |
$42.160 |
$45.500 |
risen by
7.92%
|
|
| Kip McGrath Education Centres Limited (KME) ORDINARY FULLY PAID |
Consumer Discretionary |
$38 |
Update - Notification of buy-back - KME
|
28 Apr 2026 9:27AM |
$0.580 |
$0.725 |
risen by
25%
|
|
Call 1300 880 160
Start a chat
Schedule a call
